XCR1 and neoplasm: Furthermore, the combination therapy increased migratory XCR1+CD103+ dendritic cells (DCs) in tumors and tumor-draining lymph nodes (TDLNs) while expanding CD44+CD8+ T cells with central and effector memory phenotypes.